Cardiff Oncology ($CRDF) Stock Hub 2026: The NMS Licence Dispute, The CRDF-004 Data And A Going Concern Warning

01 Executive Summary

Cardiff Oncology, Inc. is a clinical-stage biotechnology company headquartered in San Diego, California, listed on the Nasdaq Capital Market. It has no approved product, no commercial organisation, and revenue that consists of small royalty payments from a legacy diagnostics business: $145,000 for the whole of the first half of 2026. Everything that gives the equity a reason to exist is one oral small molecule called onvansertib, an inhibitor of polo-like kinase 1, and one indication, first-line RAS-mutated metastatic colorectal cancer.

Three things happened in 2026 that a reader coming to the name now has to hold at the same time, because each one changes how the other two should be read.

The first is clinical and it is the good news. The randomised, controlled Phase 2 trial known as CRDF-004 met its stated purpose, which was to select a dose and a chemotherapy backbone for a registrational programme. At the March 18, 2026 data cut, the arm combining 30 mg of onvansertib with FOLFIRI and bevacizumab produced a confirmed objective response rate of 72.2% against 42.1% for FOLFIRI and bevacizumab alone. Four patients had remained on onvansertib beyond fifteen months and two beyond twenty. The company completed an End-of-Phase 2 meeting with the Food and Drug Administration in April 2026 and says it aligned with the agency on the key design elements of a Phase 3 trial.

The second is legal and it is existential. In February 2026 Nerviano Medical Sciences S.r.l., the Italian company from which Cardiff licensed onvansertib in March 2017, sent written notice alleging material breach of the licence agreement. The alleged breach concerns inventorship: NMS says one of its employees, Dr. Barbara Valsasina, should have been named as a co-inventor on two United States patents, numbers 12,144,813 and 12,263,173. On May 19, 2026 Cardiff sued NMS in the United States District Court for the Southern District of California, seeking a declaration that it is not in material breach and an injunction requiring NMS to keep performing. On May 27, 2026, eight days later, NMS purported to terminate the agreement. Cardiff calls that termination legally ineffective, factually unsupported and procedurally improper, and says it will continue to perform. The Form 10-Q states plainly what the downside is: if the court determines that NMS’s termination was valid, the company would lose the rights granted under the agreement.

The third is financial and it constrains the other two. Cash and short-term investments fell from $58.3 million at December 31, 2025 to $34.5 million at June 30, 2026. The company completed a $10.05 million registered direct offering in July, which took the share count on the Form 10-Q cover to 77,795,249 from 68,502,000 at the balance sheet date, an increase of roughly 13.6% in six weeks. Management states that cash resources fund operations into the third quarter of 2027 and, in the same document, that this is not sufficient to meet funding requirements for the twelve months following the filing. The conclusion drawn in Note 1 is that substantial doubt exists about the ability to continue as a going concern. The auditor, BDO USA, had already included going concern language in the FY2025 audit report dated February 24, 2026.

02 The Licence Dispute That Sits Above Everything Else

Most biotechnology companies at this stage carry two risks: the drug may not work, and the money may run out. Cardiff carries a third one that is unusual and that outranks both, because it is about whether the company owns what it is developing.

Where onvansertib came from

Onvansertib was not discovered at Cardiff. It was developed at Nerviano Medical Sciences S.r.l., an Italian pharmaceutical research organisation, under the internal designation NMS-1286937. Cardiff, then still operating under its previous identity, entered into a licence agreement with NMS in March 2017, taking exclusive worldwide rights across three patent families in exchange for development milestones of up to $15 million plus royalties on any future sales. Every clinical programme the company has run since then, including CRDF-004, exists under that agreement.

What NMS alleges

In February 2026 NMS sent written notice asserting that Cardiff was in material breach. The core allegation is narrow and technical: that Dr. Barbara Valsasina, an NMS employee, should have been named as a co-inventor on two patents Cardiff obtained, United States Patent 12,144,813 and United States Patent 12,263,173, and that Cardiff refused to file a joint continuation application. In the purported termination notice of May 27, 2026, NMS invoked Section 11.3 of the agreement and widened the grounds, adding alleged breaches of the provisions requiring commercially reasonable efforts on development and on obtaining regulatory approvals.

Where the case stands

The sequence matters and it is documented in the filings.

No hearing date appears in the Q2 Form 10-Q. The company has recorded no accrual for the matter, on the basis that a loss is reasonably possible rather than probable and that the amount is not estimable. That accounting treatment is a statement about the standard for recognising a liability, not a prediction about the outcome.

Why this changes the shape of the risk

A clinical trial result is a probability. A licence termination is closer to a switch. If the court holds that NMS terminated validly, the company loses the rights to onvansertib, and onvansertib is the only clinical asset. Everything else in the pipeline is either an investigator-initiated study of the same molecule or preclinical work built on it. There is no second programme that would carry the company through an adverse ruling.

The dispute also has a visible cost even while unresolved. Selling, general and administrative expense rose by $2.6 million in the first half of 2026 against the prior year, and the company attributes part of that increase to attorney costs related to the licensing dispute, alongside severance agreements from the January management changes. That is money leaving a balance sheet that management has already described as insufficient for twelve months.

03 What The Company Actually Is Today

Cardiff Oncology has one clinical asset, one lead indication, roughly forty-five employees’ worth of operating cost and no product revenue. Its income statement recorded $104,000 of royalty revenue in the second quarter of 2026 and $145,000 for the half. Those royalties come from a legacy diagnostics business and are immaterial to the story in every sense except one: they are the only revenue line that exists.

The company was founded as Trovagene, a molecular diagnostics business, and repositioned into oncology therapeutics before adopting the Cardiff Oncology name. That history explains the residual royalties and it explains why the share register carries a long tail of retail holders from earlier eras.

The shape of the cost base tells a specific story about 2026. Research and development spending nearly halved between the two half-years, from $22.06 million to $12.68 million, and the company attributes that to the completion of clinical trials, to fewer patients remaining on treatment in the Phase 2 colorectal study, and to a reduction in preclinical activity as attention shifted to preparing the Phase 3. Administrative spending moved the other way, rising from $7.33 million to $9.93 million on severance agreements from the January management departures, the associated stock option modifications, and the attorney costs of the NMS dispute. A company spending less on science and more on lawyers and severance in the same period is not necessarily a company in trouble, but it is a company whose reported cost reduction is doing less work than the headline suggests.

The operating footprint

There is no manufacturing, no salesforce and no commercial infrastructure. Clinical operations run through contract research organisations and academic sites. Property and equipment stood at well under $1 million on the last reported balance sheet, and the only lease liability is a small operating lease. The balance sheet is close to being cash, receivables and a set of contractual rights, which is why the licence dispute is not a peripheral legal matter but a question about the principal asset.

04 Onvansertib And The PLK1 Target

Polo-like kinase 1 is a serine-threonine kinase that regulates several steps of mitosis, the phase in which a cell divides. It controls entry into mitosis, the maturation of the centrosome, the assembly of the spindle that pulls chromosomes apart, and the final separation of the two daughter cells. In many tumours PLK1 is overexpressed, and cancer cells that are already under replication stress depend on it more heavily than normal cells do. That differential dependence is the therapeutic rationale: inhibit PLK1 and the tumour cell fails to complete division while the healthy cell, with more slack in the system, tolerates the same pressure better.

Onvansertib is an orally available small molecule described by the company as a highly specific PLK1 inhibitor. Specificity matters in this class because earlier attempts at mitotic inhibition produced substantial toxicity, particularly bone marrow suppression, which limited how much drug could be given alongside chemotherapy. The clinical claim Cardiff makes is not that onvansertib works alone in colorectal cancer but that it can be added to an existing chemotherapy regimen without stacking toxicity on top of it, and that the combination produces deeper and more durable tumour shrinkage than the regimen alone.

Why RAS-mutated colorectal cancer

RAS mutations, in the KRAS or NRAS genes, are present in a large share of metastatic colorectal cancers; the company describes the resulting group as a large, underserved patient population with high unmet need. Those patients are excluded from anti-EGFR antibody therapy, which does not work when the pathway is activated downstream of the receptor, so their first-line options are chemotherapy backbones combined with bevacizumab, an anti-angiogenic antibody. That is a large population with a treatment standard that has not changed fundamentally in years, which is what the company means when it describes an underserved setting with high unmet need. Preclinical work has linked KRAS-mutant cells to particular sensitivity to PLK1 inhibition, which is the biological argument for selecting this population rather than colorectal cancer generally.

The backbone question

The CRDF-004 design tested onvansertib against two different chemotherapy backbones, FOLFIRI with bevacizumab and FOLFOX with bevacizumab. The registrational regimen selected is the FOLFIRI combination, and the company has said so consistently since the End-of-Phase 2 meeting. The published headline numbers describe that arm. The selection is itself a data point: choosing one backbone out of two tested is a decision made on evidence, and the evidence behind the arm not selected has not been presented with the same prominence.

05 CRDF-004: Reading The Data Precisely

CRDF-004 is registered on ClinicalTrials.gov as NCT06106308. It is a randomised, controlled, open-label, dose-finding Phase 2 study in first-line RAS-mutated metastatic colorectal cancer, with a target enrolment of 110 patients. The Form 10-Q states that the trial is being conducted in partnership with Pfizer Ignite, a fee-for-service arrangement through which a larger company supplies clinical development infrastructure; it is a services relationship, not a licensing or economic partnership on the asset. Patients received onvansertib at 20 mg or 30 mg on top of either FOLFIRI with bevacizumab or FOLFOX with bevacizumab, against control arms receiving the standard-of-care regimen alone. The primary endpoint is objective response rate; secondary endpoints include progression-free survival, duration of response, disease control rate, overall survival, adverse events and pharmacokinetics. The registry lists the study as active and no longer recruiting, with primary completion estimated for November 2026 and study completion for January 2027.

What the trial was designed to do

The company describes the primary goal as selecting the efficacious and safe dose of onvansertib plus a standard-of-care regimen for the registrational programme, and states that the trial achieved that goal. This framing is accurate and it is also a limitation that gets lost in coverage. A dose-selection study is built to choose between arms, not to prove a treatment effect against a control with statistical rigour. The arms are small, the study is open-label, and it was never powered to demonstrate superiority.

The progression-free survival numbers, and why they moved

This is the part of the record that requires care, because the reported hazard ratio has changed across data cuts and the direction of the change matters.

Two observations follow directly from the table. The hazard ratio moved unfavourably between the January topline and the March cut, from 0.37 or 0.38 to 0.55 or 0.57. And the confidence intervals published for the March cut both include 1.0, the value at which there is no difference between arms. An interval running from 0.15 to 2.09 is consistent with a large benefit, with no benefit, and with harm. That is what small arms produce, and it is why the trial is a dose-selection study rather than a registrational one. The January release carried a p value below 0.05 against combined standard of care; the more recent presentation of the March cut carries confidence intervals instead, and those intervals do not exclude the null.

The objective response rate separation is the more robust of the two signals, because response rate is a simpler measurement taken earlier and a thirty-point gap is large. It is still a gap measured in an open-label study across arms of modest size.

Durability and safety

The company reports that responses in the onvansertib arm were deeper and more durable, that four patients remained on onvansertib treatment beyond fifteen months and two beyond twenty months. At the June 23, 2026 data cut, 12 patients remained on trial: 8 in the onvansertib 20 mg or 30 mg plus FOLFIRI and bevacizumab arms and one on standard of care. Duration on treatment past twenty months in first-line metastatic colorectal cancer is a meaningful observation in itself, though a handful of long responders is not a substitute for a survival curve.

On tolerability the record is consistent across releases: the combination continued to be well tolerated with no major or unexpected toxicities and no additive adverse events observed when onvansertib was added to standard of care. Neutropenia has been described as the most common treatment-emergent event, and grade 3 or higher events as infrequent. For a mitotic inhibitor added to cytotoxic chemotherapy, the absence of additive toxicity is the technical claim the whole programme depends on.

06 The Registrational Plan And What Is Still Missing From It

Cardiff completed an End-of-Phase 2 meeting with the FDA in April 2026. That is a Type B meeting, the formal point at which a sponsor and the agency discuss whether the existing data support moving into a registrational programme and what that programme should look like. The company says it aligned with the agency on the key design elements.

What has been disclosed about the trial

The planned study is randomised and controlled, evaluating 30 mg of onvansertib in combination with FOLFIRI and bevacizumab against FOLFIRI and bevacizumab alone, as first-line therapy in patients with RAS-mutated metastatic colorectal cancer. The company has indicated an expected enrolment of approximately 640 patients across the United States, Europe and other regions, and has begun a scientific advice process with the European Medicines Agency. Initiation is planned for the first quarter of 2027.

The clause that governs everything

The August 11 release states the timing twice and attaches the same condition both times: the company is preparing to initiate the trial in the first quarter of 2027, subject to securing additional financing. That phrase does the work of a footnote and carries the weight of the whole plan. A 640-patient global Phase 3 in oncology is a multi-year commitment measured in hundreds of millions of dollars, run by a company that reported $34.5 million of cash at June 30, 2026 and a market value near $76.3 million.

The arithmetic gap between those numbers is not a detail to be resolved later. It is the reason the trial start date is conditional, and it means one of three things has to happen before the first patient is dosed: a partnership or licensing deal that brings in a larger counterparty’s balance sheet, an equity raise of a size that would transform the share count, or a materially different trial design from the one described.

What has not been published

The disclosures stop short of several things a reader would need to model the programme. There is no stated primary endpoint for the Phase 3, no interim analysis plan, no statistical assumptions, no registration on ClinicalTrials.gov as of August 12, 2026, and no site list. The FY2025 Form 10-K refers to an earlier Type C meeting in June 2023 at which the agency discussed a design with an interim response-rate and duration-of-response readout for possible accelerated approval and progression-free survival with no detriment to overall survival for full approval. Whether that framework survived into the April 2026 alignment is not stated in the current filings.

07 The Rest Of The Pipeline

Everything below the colorectal programme is the same molecule in other settings, and almost all of it is sponsored by academic institutions rather than by Cardiff. That structure keeps the cost low and it also means the company does not control the timelines.

Cardiff appears as a collaborator rather than lead sponsor on the four investigator-initiated studies. Enrolment targets are small, between 21 and 90 patients, which is appropriate for signal-seeking work and insufficient for registration. None of these studies would support a marketing application on its own, and none is funded in a way that would let Cardiff accelerate it.

The antibody-drug conjugate work

At the 2026 American Association for Cancer Research annual meeting in April, the company presented preclinical data showing that onvansertib enhanced the activity of trastuzumab deruxtecan, a HER2-targeted antibody-drug conjugate, driving tumour regression and overcoming resistance in HER2-low breast cancer models. The word carrying the weight in that sentence is preclinical. These are mouse models, not patients. The scientific logic is coherent, since antibody-drug conjugates deliver a cytotoxic payload that acts on dividing cells and a mitotic inhibitor could plausibly potentiate it, and the commercial logic is obvious, since trastuzumab deruxtecan is a large and growing product. Neither makes it a clinical asset. There is no trial of that combination in humans.

Regulatory designations

A review of the FY2025 Form 10-K found no Fast Track, Orphan Drug or Breakthrough Therapy designation attached to onvansertib. The references to orphan drug status in that document describe the regulatory framework in general terms rather than any grant to the company. Coverage that implies otherwise should be checked against the filings.

08 Second Quarter 2026 Financial Position

The numbers below come from the results release and the Form 10-Q, both filed on August 11, 2026, and they cross-check against each other and against the first quarter release.

The gap between reported expenses and cash consumption

Total operating expenses for the first half fell by $6.8 million against the prior year, from $29.4 million to $22.6 million. Net cash used in operating activities moved the other way, rising by $3.0 million from $21.1 million to $24.1 million. The two lines diverge because expense recognition and cash payment are different events: severance obligations, accrued liabilities from the wound-down trial and legal fees are settled on their own schedule. Accounts payable, which stood at $8.1 million at December 31, 2025, had fallen to $5.5 million by March 31, and paying down payables consumes cash without appearing as an expense in the period. A reader using the expense line as a proxy for burn will understate the rate at which the balance sheet is depleting.

Balance sheet

Working capital was $24.8 million at June 30, 2026 against $43.7 million at December 31, 2025. Cash and cash equivalents were $9.2 million with short-term investments of $25.3 million. There is no financial debt: the only non-operating liabilities are small operating lease obligations, with $457,000 in the current portion and nothing beyond twelve months. No lender therefore holds a claim ahead of shareholders and no covenant can be tripped, which removes one category of risk that affects many companies in this position without changing the funding requirement itself.

09 Going Concern: What The Filing Says And What It Means

The Q2 Form 10-Q contains a going concern disclosure in Note 1 and repeats the substance of it in management’s discussion and analysis. The company reports $34.5 million of cash, cash equivalents and short-term investments at June 30, 2026, states that this is not sufficient to meet funding requirements for at least the twelve months following the filing, and records management’s conclusion that substantial doubt exists about the ability to continue as a going concern. The financial statements are prepared on a going concern basis, which is standard practice when management intends to continue operating.

The apparent contradiction, resolved

The results release says cash resources are sufficient to fund operations into the third quarter of 2027. The Form 10-Q says the resources are not sufficient for twelve months from the filing date. Both statements are true and they are not in conflict. The filing date is August 11, 2026, so the twelve-month test reaches to August 2027. A runway that ends inside the third quarter of 2027, which runs from July to September, does not clear an August 2027 test with certainty. The accounting standard requires the conclusion whenever the runway does not comfortably exceed the horizon, regardless of how close the margin is.

A reader who takes only the press release headline will register an extended runway. A reader who opens the 10-Q will register a going concern conclusion. Both documents were filed on the same day by the same company.

This is not new

BDO USA, the company’s auditor since 2007, included going concern language in its report on the FY2025 financial statements, dated February 24, 2026, citing recurring losses from operations and negative operating cash flows. The Q2 2026 disclosure continues a condition that was already documented at the start of the year rather than introducing one.

What it does and does not signal

A going concern conclusion is a statement about the relationship between cash on hand and a twelve-month horizon. It is not a statement that the company is failing, that the science is wrong, or that insolvency is imminent. Many clinical-stage biotechnology companies carry the language for years and resolve it repeatedly by raising capital. What it does establish is that the funding question has a deadline attached to it, that the deadline is inside the next twelve months, and that any equity issued to answer it will be issued by a company whose auditor and management have both put that condition in writing. Capital raised from a position described in those terms is rarely raised on favourable terms.

10 Capital Structure And The Cost Of Staying Alive

The share count is the number that changed most in 2026, and the way it changed illustrates what financing looks like from this position.

The July 2026 registered direct offering

On July 14, 2026 the company entered into a securities purchase agreement, closing on July 16. Institutional investors bought 8,571,429 shares with accompanying warrants at $1.05 per unit. Insiders bought a further 721,649 units at $1.455. Gross proceeds were approximately $10.05 million. The warrants carry an exercise price of $1.31 for the institutional tranche and $1.33 for the insider tranche, and they cannot be exercised before the later of six months from issuance or the date on which the authorised share count is increased. H.C. Wainwright acted as placement agent, taking a 7% cash fee and warrants over 465,157 shares at $1.3125. The offering was made off a shelf registration statement effective since May 13, 2025.

Two structural details sit inside that transaction. Insiders paid $1.455 while institutions paid $1.05, a premium that reflects Nasdaq rules on insider participation rather than any view about value. And the warrants cannot be exercised until shareholders approve an increase in authorised shares, which the company committed to seek by filing a proxy within 45 days of closing and to keep re-proposing every 60 days until it passes or the warrants expire.

The authorised-share vote: preliminary proxy filed August 14, 2026

Cardiff filed a preliminary proxy statement on August 14 calling a special meeting of stockholders for October 2026. The exact date and the record date are left blank in the preliminary version and will be fixed in the definitive filing. Two items are on the agenda: an amendment to the certificate of incorporation raising authorised capital stock from 170,000,000 to 320,000,000 shares and authorised common stock from 150,000,000 to 300,000,000, and a routine proposal to adjourn the meeting if the votes for the first are not there.

The arithmetic is the point. With 77,795,249 shares outstanding on the August 6 cover, the current 150 million ceiling already carries the July offering, the warrants attached to it and the equity plans. Doubling the ceiling to 300 million creates roughly 220 million shares of unissued headroom against a company that reported substantial doubt about its ability to continue as a going concern in the same quarter. That headroom is not an issuance and does not have to be used. It is the precondition for one, and it is also the precondition for the July warrants becoming exercisable at all, which is why the company undertook to keep bringing the resolution back every sixty days until it passes.

Dilution, measured

Shares outstanding were 68,502,000 at June 30, 2026 and 77,795,249 on the Form 10-Q cover dated August 6, 2026. That is an increase of about 13.6% inside six weeks, for roughly $10.05 million of gross proceeds. Set against a company that consumed $24.1 million of operating cash in six months, the raise buys somewhere in the region of a quarter.

The potentially dilutive securities excluded from the loss-per-share calculation at June 30, 2026 were 11,788,535 options, 432 legacy warrants and Series A convertible preferred stock equivalent to 877 shares. That table predates the July offering, so it does not include the roughly 9.3 million new warrants or the placement agent warrants. Adding them to the outstanding count gives a fully diluted picture well above 98 million shares before any further financing.

The listing threshold

The stock closed at $1.05 on August 11, 2026 and traded at $0.99 in the pre-market session of August 12. Nasdaq requires a minimum bid price of $1.00 for continued listing, with a deficiency notice issued after 30 consecutive business days below that level. A search of EDGAR filings for this issuer covering 2025 and 2026 found no Item 3.01 notice and no reference to minimum bid price compliance, so no deficiency has been disclosed as of August 12, 2026. The FY2025 Form 10-K carries a general listing risk factor of the kind most small-cap issuers include. The share price sitting on the threshold is a fact; a compliance problem is not yet one.

11 Governance: A Management Team Rebuilt In One Year

On January 27, 2026 both the chief executive officer and the chief financial officer resigned with immediate effect, in what the company described as a strategic leadership review. Departures of that kind, taken together and without a successor named, are read badly by markets, and this one was announced on the same day as a positive clinical update. The filings record no restatement, no investigation and no disagreement over accounting.

The rebuild took roughly ten weeks and is now complete.

Dr. Mohindru moved from the board into the interim role and then into the permanent one, and continues as a director. The former chief executive, Dr. Mark Erlander, resigned from the board on March 27, 2026 when the separation agreements were formalised. The severance arrangements from those departures are a visible line in the 2026 cost base, contributing to the $2.6 million rise in administrative expense.

Insider participation

Insiders bought 721,649 units in the July 2026 offering at $1.455, above the $1.05 paid by institutions. Under Nasdaq rules that premium is required rather than voluntary, so it should not be read as a price signal. Officers and directors as a group held 5,831,354 shares, or 8.5%, at the April 20, 2026 record date, and a substantial part of the largest individual holdings consists of exercisable options rather than purchased stock. The largest holding among sitting directors is Gary W. Pace with 1,473,350 shares, or 2.2%.

Institutional register

The proxy statement filed April 23, 2026 names two 5% holders: BlackRock at 3,841,097 shares, or 5.6%, and The Vanguard Group at 3,728,334 shares, or 5.5%. Both figures rest on Schedule 13G filings made during 2025 rather than on current data, because no Schedule 13G or 13D more recent than November 2024 appears on EDGAR for this issuer. Index-tracking positions of that kind reflect membership of a small-cap benchmark rather than any conviction about the programme.

The annual meeting

Shareholders met on June 11, 2026, electing six directors, ratifying BDO USA as auditor for FY2026, approving an increase in the shares available under the 2021 incentive plan to 15,150,000, and passing the advisory vote on executive compensation. A separate meeting to increase authorised share capital, required before the July warrants become exercisable, had not been scheduled as of August 12, 2026.

12 Market Data

Market figures move constantly and every number in this section carries the timestamp of the reading that produced it.

Three features of that table describe the trading character of the name. The stock sits roughly 70% below its 52-week high and roughly 31% above its 52-week low, which is the profile of a security that has repriced heavily and then stabilised at a lower level. Short interest at 17.5% of float with a short ratio near eight means a large position that would take days of average volume to close, which cuts both ways: it magnifies moves in either direction. And a price under a dollar with an average volume of 1.5 million shares means the daily dollar turnover is small enough that ordinary position sizes move the price.

The run into the Q2 release is visible in the tape. The stock traded at $0.818 on July 28 and closed at $1.05 on August 11, a rise of about 28% in ten sessions, with volume above one million shares on several of those days. The pre-market reaction on August 12 was negative.

13 Retail Sentiment

The figures below come from the Stocktwits pulse for the symbol, read on August 12, 2026. They measure what non-professional traders are posting, not what analysts or institutions think, and they age in hours.

What the stream is actually discussing

Three themes dominate the posts around the Q2 release, and they are worth summarising because they show where retail attention differs from what the filings emphasise.

The first is the court case. Posts speculate about when the judge might rule on the preliminary injunction, with dates proposed on no visible basis, and the language used about NMS is hostile, describing the dispute as extortion. The filings contain no such characterisation and no ruling date.

The second is the runway. Several posters expressed surprise that cash reaches into the third quarter of 2027, having expected the year end, and read that as bullish. None of the posts reviewed referenced the going concern conclusion in the same filing.

The third is extrapolated efficacy. At least one widely shared post projects a median progression-free survival of roughly 21 months for the 30 mg arm, derived by the poster from published data cuts rather than reported by the company. Cardiff has not published a median progression-free survival figure for that arm.

These are the observations of individual traders, not of professional analysts, and none of them has been verified against a primary source because none of them originates from one.

14 The Case Made By Those Who Are Constructive

The arguments below are the ones supporters of the company put forward. They are set out as their case, not as a conclusion.

The response rate separation is large and was produced in a randomised, controlled setting. A confirmed objective response rate of 72.2% against 42.1% on the same chemotherapy backbone is a thirty-point gap, and randomisation removes the selection effects that make single-arm data hard to interpret. Response rate is measured earlier and more objectively than survival endpoints, and a gap of that size is not usually produced by noise alone.

The tolerability profile is the enabling fact. Adding a mitotic inhibitor to cytotoxic chemotherapy would normally be expected to compound myelosuppression. Across every data cut the company has reported no additive adverse events and no unexpected toxicities. If that holds in a larger trial, it means the combination can be given at full dose to a broad first-line population rather than to a fit subset.

The FDA has engaged at the registrational level. An End-of-Phase 2 meeting completed in April 2026 with alignment on key design elements is a concrete regulatory step, not a press release. It establishes that the agency considers the existing package sufficient to define a pivotal trial.

The durability observations are unusual. Four patients beyond fifteen months on treatment and two beyond twenty months in first-line metastatic colorectal cancer is a long tail. Supporters read that as consistent with a deepening of response rather than a transient effect.

The target population is large and underserved. RAS mutations occur in roughly half of metastatic colorectal cancers and exclude those patients from anti-EGFR therapy. The standard of care in that setting has been static, so an incremental improvement on top of an existing backbone faces a low bar in terms of practice change.

There is no debt. The balance sheet carries no borrowings, only small operating leases. Whatever happens to the equity, there is no lender with a claim ahead of shareholders and no covenant that can be tripped.

The valuation embeds severe outcomes. At a market value near $76.3 million against $34.5 million of cash before the July raise, the enterprise value ascribed to a Phase 2-validated asset with an agreed registrational path is small. Supporters argue that the discount reflects the licence dispute and the funding gap rather than the science, and that resolution of either would remove it.

15 The Case Made By Those Who Are Sceptical

These are the arguments on the other side, set out on the same basis.

The company may not own its drug. This is the argument that subsumes the others. NMS has purported to terminate the licence and Cardiff’s own filing states that a court finding in NMS’s favour would strip the rights granted under the agreement. There is no second asset. No amount of clinical progress protects against that outcome, and the timing of a ruling is outside the company’s control.

The progression-free survival evidence weakened between data cuts. The hazard ratio moved from 0.37 and 0.38 at the January cut to 0.55 and 0.57 at the March cut, and the confidence intervals published for the March cut run from 0.15 to 2.09 and from 0.20 to 1.65. Both include 1.0. Sceptics read a hazard ratio that deteriorates as follow-up matures, in a small open-label study, as the pattern of an early effect that regresses rather than consolidates.

The trial was never designed to prove efficacy. The company itself describes the primary goal as dose selection. Reading a dose-selection study as a demonstration of benefit is a category error, and the arms are small enough that a handful of patients moves any percentage materially.

The Phase 3 is unfunded and the company says so. A 640-patient global oncology trial against $34.5 million of cash and a market value near $76.3 million is not a financing gap that can be closed by ordinary dilution. The start date is explicitly conditional, which means it can slip indefinitely without the company having broken any commitment.

Going concern is now a documented management conclusion. Not merely an auditor’s caveat carried forward, but a conclusion reached and stated in the second quarter filing. Capital raised against that background is raised on the buyer’s terms.

The July offering shows what those terms look like. Roughly $10.05 million of gross proceeds for a 13.6% increase in the share count, plus warrants that will add nearly ten million more shares if exercised, from a company that consumed $24.1 million of operating cash in six months. Extrapolating that exchange rate to the sum a Phase 3 requires gives a share count that bears no relationship to today’s.

The stock is under a dollar. No deficiency notice has been issued, but the threshold is where it is, and a company that needs to issue equity from below $1.00 has fewer options than one issuing from above it.

Everything beyond colorectal cancer is thin. Four investigator-initiated studies that Cardiff does not sponsor, with enrolment targets between 21 and 90 patients, and one preclinical combination in mouse models. Sceptics read the antibody-drug conjugate work as an attempt to widen the story rather than as a second programme.

16 Scenario Framework

The two paths below describe what would have to happen for each to unfold. They are not forecasts, they carry no probabilities and no price levels.

The variable separating the two is not the clinical data. It is the ruling on the injunction, because everything else, including the ability to finance a Phase 3 and the willingness of any partner to engage, sits downstream of whether Cardiff can be confident it holds the rights. The checkpoints the record actually supplies are: a decision on the preliminary injunction, fully briefed since July 24, 2026 with no hearing date published; primary completion of CRDF-004, estimated at November 2026 on the trial registry; a special shareholder meeting to increase authorised shares, committed to within 45 days of the July 16 closing; and the planned Phase 3 initiation in the first quarter of 2027, conditioned on financing.

17 Bottom Line

Two accurate and opposite descriptions of Cardiff Oncology can be drawn from the same filings. The first is a company that ran a randomised controlled trial in a hard first-line setting, produced a thirty-point response-rate separation with no additive toxicity, selected a dose and regimen, completed an End-of-Phase 2 meeting at which the FDA aligned on the design of a pivotal study, rebuilt its entire executive team inside ten weeks, carries no debt, and trades at a market value near $76.3 million with $34.5 million of cash behind it. The second is a company whose licensor has purported to terminate the agreement covering its only asset, whose management has concluded that substantial doubt exists about its ability to continue as a going concern, whose progression-free survival hazard ratio worsened between two consecutive data cuts with confidence intervals that include no effect, whose pivotal trial is explicitly conditioned on money it does not have, and whose shares trade below the Nasdaq minimum bid threshold. Both descriptions are supported by documents filed on August 11, 2026.

What is verified. Cash, cash equivalents and short-term investments of $34.5 million at June 30, 2026, down from $46.1 million at March 31 and $58.3 million at December 31, 2025. Operating cash consumption of $24.1 million in the first half against $21.1 million a year earlier. Net loss of $9.232 million in the second quarter and $21.577 million in the half, at $0.14 and $0.32 per share. Research and development of $12.680 million and administrative expense of $9.930 million for the half. Royalty revenue of $145,000. A stated runway into the third quarter of 2027 and, in the same filing, a management conclusion of substantial doubt about going concern, with BDO having flagged the same condition in the FY2025 audit report of February 24, 2026. A registered direct offering closed July 16, 2026 for approximately $10.05 million gross, taking shares outstanding from 68,502,000 at June 30 to 77,795,249 on the Form 10-Q cover of August 6. A confirmed objective response rate of 72.2% against 42.1% and progression-free survival hazard ratios of 0.55 and 0.57, with confidence intervals of 0.15 to 2.09 and 0.20 to 1.65, all at the March 18, 2026 data cut. Twelve patients still on trial at the June 23 cut. A licence agreement entered into in March 2017, a breach notice in February 2026, Cardiff’s suit of May 19, NMS’s purported termination of May 27, and a preliminary injunction motion fully briefed since July 24 and awaiting decision.

What is not verified. The merits of the licence dispute, on which no court has ruled and for which the operative contractual language is not public. Any hearing or decision date for the injunction. The primary endpoint, statistical assumptions and interim analysis plan for the planned Phase 3, none of which has been published, and which is not registered on ClinicalTrials.gov as of August 12, 2026. How the Phase 3 would be funded. Any median progression-free survival figure for the 30 mg arm, which the company has not published despite figures circulating in retail discussion. Current institutional ownership, since no Schedule 13G or 13D more recent than November 2024 appears on EDGAR for this issuer. And analyst coverage, since no individual note could be confirmed with both house and exact date.

The dates that settle the question: no published date, for the ruling on the preliminary injunction, which is the single event on which the ownership of the asset turns; November 2026, the estimated primary completion of CRDF-004 on the trial registry, which produces the full data set against which the March cut will be judged; by late August 2026, the contractual deadline for filing a proxy to increase authorised shares; and the first quarter of 2027, the planned Phase 3 initiation, which the company has twice stated is subject to securing additional financing.